Navigation Links
Apligraf® Approved by Saudi Food and Drug Authority for Treatment of Chronic Wounds
Date:9/28/2010

CANTON, Mass., Sept. 28 /PRNewswire/ -- Organogenesis, Inc. announced that its Apligraf® bilayered living cellular construct has been approved for the treatment of diabetic foot ulcers and other chronic wounds by the Saudi Food and Drug Authority (SFDA) of the Kingdom of Saudi Arabia. Apligraf is a living cell based product used by physicians to heal chronic wounds in patients in the U.S. and around the world.

"With diabetes being a widespread and growing medical problem in Saudi Arabia and other Gulf States, the incidence of Diabetic Foot Ulcers is expected to increase," explained Dr. Damien Bates, M.D., Ph. D., F.R.A.C.S. (Plast.), and Chief Medical Officer at Organogenesis. "The prevalence of diabetes is now nearly 14% and expected to increase to 19% by 2030, the highest incidence in the Middle East nations."

The Kingdom of Saudi Arabia, with a population of more than 29 million, is the largest and most affluent of the Gulf Co-operation Council countries. It has built one of the most comprehensive healthcare systems in the Middle East.

Diabetic foot ulcers are open wounds that, for a variety of reasons, fail to heal by the body's own systems. The lifetime risk of a person with diabetes developing a foot ulcer could be as high as 25%. The International Diabetes Federation reports that 285 million people around the world suffer from diabetes.

Apligraf was the first bioengineered cell based product to receive U.S. FDA approval for chronic wounds. Clinical studies have shown that Apligraf in combination with a standard therapy is more efficient in healing diabetic foot ulcers or venous leg ulcers than standard therapy alone.(i,ii)

About Apligraf®

Apligraf® contains two layers of human living cells: an outer protective layer of differentiated keratinocytes and an inner layer of fibroblasts in a collagen matrix. When placed on a wound previously unresponsive to treatment, Apligraf provides cells, collagen matrix and other proteins that provide a covering that has been demonstrated to promote healing. In multiple controlled clinical studies, Apligraf has been shown to be an effective and safe wound care treatment, superior to conventional treatments.

About Organogenesis, Inc.

Having pioneered the field, Massachusetts based Organogenesis, Inc. is a leading regenerative medicine company focused in the areas of bioactive wound healing, oral regeneration and biosurgery. The company's mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care. For more information, visit www.organogenesis.com.

(i) Veves A, Falanga V, Armstrong DG, Sabolinski ML. Diabetic Foot Ulcer Study Group. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24: 290–5.

(ii) Falanga V, Sabolinski M. A bilayered living skin construct. (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Rep Reg 1999; 7:210-207.


'/>"/>
SOURCE Organogenesis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016   ... Growth in Recurring Consumable Sales  Clinical sales ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... sales for the first quarter ended March 31, 2016 ... execution of its commercial strategy. First Quarter ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
(Date:4/27/2016)... 2016 Tie-up with Government hospitals ... to save newborns   Fortis La Femme, ... in collaboration with Breast Milk Foundation (BMF), a non-profit organization ... Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes ... infants and should be available to babies deprived of mother,s ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, ... addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization ... optimization products to the store is just one more way Shamangelic Healing supports ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... flexibility in repaying their loans, more information about their loan terms and accounts, ... outstanding student loan debt, including federal and private loans, has reached $1.3 trillion, ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the 2016 ... the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee Award ...
(Date:4/29/2016)... ... 2016 , ... Dr. Robert Mondavi, one of the dentists in Torrance ... a fast-growing field as more patients are discovering the many different ways they can ... options currently available to them and which ones might work for their smiles. ...
(Date:4/29/2016)... ... 29, 2016 , ... Innovations with Ed Begley Jr., announced ... airing third quarter 2016 via Discovery Channel. Dates and show times TBA. , ... located in Greenwood, Wisconsin applies product research and development and continuous technological improvements ...
Breaking Medicine News(10 mins):